Fluenz

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
03-12-2014
Summary of Product characteristics Summary of Product characteristics (SPC)
03-12-2014
Public Assessment Report Public Assessment Report (PAR)
03-12-2014

Active ingredient:

Реассортанта вируса на грипа (на живо аттенуированная) следните щамове:a/Калифорния/7/2009 pdm09 (Н1N1)като щам А/Виктория/361/2011 (Н3N2), като напрежение, B/Масачузетс/2/2012 на щам

Available from:

MedImmune LLC

ATC code:

J07BB03

INN (International Name):

influenza vaccine (live attenuated, nasal)

Therapeutic group:

Ваксини

Therapeutic area:

Influenza, Human; Immunization

Therapeutic indications:

Профилактика на грип при индивиди на възраст 24 месеца до 18-годишна възраст. Използването на Fluenz трябва да се основава на официални препоръки.

Product summary:

Revision: 4

Authorization status:

Отменено

Authorization date:

2011-01-27

Patient Information leaflet

                                22
Б. ЛИС
ТОВКА
Лекарствен продукт, който вече не е
разрешен за употреба
23
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
FLUENZ СПРЕЙ ЗА НОС, СУСПЕНЗИЯ
Ваксина срещу грип (жива атенюирана,
назална) (Influenza vaccine (live attenuated, nasal))
Този лекарствен продукт подлежи на
допълнително наблюдение. Това ще
позволи бързото
установяване на нова информация
относно безопасността. Можете да
дадете своя принос като
съобщите всяка нежелана реакция,
която сте получили. За начина на
съобщаване на нежелани
реакции вижте края на точка 4.
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ПРИЛОЖИТЕ ВАКСИНАТА, ТЪЙ КАТО
ТЯ
СЪДЪРЖА ВАЖНА ЗА ВАС ИЛИ ЗА ВАШЕТО
ДЕТЕ ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
медицинска
сестра или фармацевт.
-
Тази ваксина е предписана единствено
и лично на Вас или на Вашето дете.
Не я преотст
ъпвайте на друг
и хора.
-
Ако някоя от нежеланите лекарствени
реакции стане сериозна, уведомете
Вашия лекар,
медицинска сестра или фармацевт. Това
включва всички възможни, неописани в
тази
листовка нежелани реакции. Вижте
точка 4.
КАКВО СЪДЪР
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕР
ИСТИКА НА ПРОД
УКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
Този лекарствен продукт подлежи на
допълнително наблюдение. Това ще
позволи бързото
установяване на нова информация
относно безопасността. От
медицинските специалисти се
изисква да съобщават всяка подозирана
нежелана реакция. За начина на
съобщаване на
нежелани реакции вижте точка 4.8.
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
FLUENZ спрей за нос, суспензия
Ваксина срещу грип (жива ат
енюирана, назална) (Influenza vaccine (live att
enuated, nasal)
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Реасортантен грипен вирус* (жив
атенюиран) от следните щамове**:
A/California/7/2009 (H1N1)pdm09-подобен щам
(A/California/7/2009, MEDI 228029)
10
7,0±0,5
FFU***
A/Victoria/361/2011 (H3N2)-подобен щам
(A/Texas/50/2012, MEDI 237514)
10
7,0±0,5
FFU***
B/Massachusetts/2/2012-подобен щам
(B/Massachusetts/2/2012, MEDI 237751)
10
7,0±0,5
FFU***
.......................................................................................................на
доза от 0,2 ml
*
култивиран в оплодени кокоши яйца от
млади здрави птици.
**
култивиран във VERO клетки чрез
реверсивна генна технология. Този
продукт
съдържа генномодифицирани организми
(ГМО).
***
флуоресцентни фокусни единици (fluorescent
focus units)
Ваксината отговаря на препоръките 
                                
                                Read the complete document

Similar products

Active ingredient Реассортанта вируса на грипа (на живо аттенуированная) следните щамове:a/Калифорния/7/2009 pdm09 (Н1N1)като щам А/Виктория/361/2011 (Н3N2), като напрежение, B/Масачузетс/2/2012 на щам

Реассортанта вируса на грипа (на живо аттенуированная) следните щамове:a/Калифорния/7/2009 pdm09 (Н1N1)като щам А/Виктория/361/2011 (Н3N2), като напрежение, B/Масачузетс/2/2012 на щам

ATC code J07BB03

J07BB03

Marketed by MedImmune LLC

MedImmune LLC

INN (International Name) influenza vaccine (live attenuated, nasal)

influenza vaccine (live attenuated, nasal)

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 03-12-2014
Summary of Product characteristics Summary of Product characteristics Spanish 03-12-2014
Public Assessment Report Public Assessment Report Spanish 03-12-2014
Patient Information leaflet Patient Information leaflet Czech 03-12-2014
Summary of Product characteristics Summary of Product characteristics Czech 03-12-2014
Public Assessment Report Public Assessment Report Czech 03-12-2014
Patient Information leaflet Patient Information leaflet Danish 03-12-2014
Summary of Product characteristics Summary of Product characteristics Danish 03-12-2014
Public Assessment Report Public Assessment Report Danish 03-12-2014
Patient Information leaflet Patient Information leaflet German 03-12-2014
Summary of Product characteristics Summary of Product characteristics German 03-12-2014
Public Assessment Report Public Assessment Report German 03-12-2014
Patient Information leaflet Patient Information leaflet Estonian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Estonian 03-12-2014
Public Assessment Report Public Assessment Report Estonian 03-12-2014
Patient Information leaflet Patient Information leaflet Greek 03-12-2014
Summary of Product characteristics Summary of Product characteristics Greek 03-12-2014
Public Assessment Report Public Assessment Report Greek 03-12-2014
Patient Information leaflet Patient Information leaflet English 03-12-2014
Summary of Product characteristics Summary of Product characteristics English 03-12-2014
Public Assessment Report Public Assessment Report English 03-12-2014
Patient Information leaflet Patient Information leaflet French 03-12-2014
Summary of Product characteristics Summary of Product characteristics French 03-12-2014
Public Assessment Report Public Assessment Report French 03-12-2014
Patient Information leaflet Patient Information leaflet Italian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Italian 03-12-2014
Public Assessment Report Public Assessment Report Italian 03-12-2014
Patient Information leaflet Patient Information leaflet Latvian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Latvian 03-12-2014
Public Assessment Report Public Assessment Report Latvian 03-12-2014
Patient Information leaflet Patient Information leaflet Lithuanian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-12-2014
Public Assessment Report Public Assessment Report Lithuanian 03-12-2014
Patient Information leaflet Patient Information leaflet Hungarian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Hungarian 03-12-2014
Public Assessment Report Public Assessment Report Hungarian 03-12-2014
Patient Information leaflet Patient Information leaflet Maltese 03-12-2014
Summary of Product characteristics Summary of Product characteristics Maltese 03-12-2014
Public Assessment Report Public Assessment Report Maltese 03-12-2014
Patient Information leaflet Patient Information leaflet Dutch 03-12-2014
Summary of Product characteristics Summary of Product characteristics Dutch 03-12-2014
Public Assessment Report Public Assessment Report Dutch 03-12-2014
Patient Information leaflet Patient Information leaflet Polish 03-12-2014
Summary of Product characteristics Summary of Product characteristics Polish 03-12-2014
Public Assessment Report Public Assessment Report Polish 03-12-2014
Patient Information leaflet Patient Information leaflet Portuguese 03-12-2014
Summary of Product characteristics Summary of Product characteristics Portuguese 03-12-2014
Public Assessment Report Public Assessment Report Portuguese 03-12-2014
Patient Information leaflet Patient Information leaflet Romanian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Romanian 03-12-2014
Public Assessment Report Public Assessment Report Romanian 03-12-2014
Patient Information leaflet Patient Information leaflet Slovak 03-12-2014
Summary of Product characteristics Summary of Product characteristics Slovak 03-12-2014
Public Assessment Report Public Assessment Report Slovak 03-12-2014
Patient Information leaflet Patient Information leaflet Slovenian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Slovenian 03-12-2014
Public Assessment Report Public Assessment Report Slovenian 03-12-2014
Patient Information leaflet Patient Information leaflet Finnish 03-12-2014
Summary of Product characteristics Summary of Product characteristics Finnish 03-12-2014
Public Assessment Report Public Assessment Report Finnish 03-12-2014
Patient Information leaflet Patient Information leaflet Swedish 03-12-2014
Summary of Product characteristics Summary of Product characteristics Swedish 03-12-2014
Public Assessment Report Public Assessment Report Swedish 03-12-2014
Patient Information leaflet Patient Information leaflet Norwegian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Norwegian 03-12-2014
Patient Information leaflet Patient Information leaflet Icelandic 03-12-2014
Summary of Product characteristics Summary of Product characteristics Icelandic 03-12-2014
Patient Information leaflet Patient Information leaflet Croatian 03-12-2014
Summary of Product characteristics Summary of Product characteristics Croatian 03-12-2014
Public Assessment Report Public Assessment Report Croatian 03-12-2014

Search alerts related to this product

Alerts Fluenz Реассортанта вируса на грипа influenza vaccine

Fluenz Реассортанта вируса на грипа influenza vaccine

View documents history

Documents history Documents history

Fluenz